Zacks Small Cap Decreases Earnings Estimates for Soligenix

Soligenix, Inc. (NASDAQ:SNGX) – Analysts at Zacks Small Cap dropped their FY2025 earnings per share estimates for Soligenix in a research note issued to investors on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will post earnings per share of ($3.09) for the year, down from their prior estimate of ($2.93). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s FY2026 earnings at ($2.02) EPS.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 223.29%. During the same quarter in the previous year, the company posted ($12.66) EPS.

Soligenix Stock Performance

Shares of SNGX stock opened at $2.21 on Friday. Soligenix has a fifty-two week low of $1.83 and a fifty-two week high of $14.92. The firm has a market capitalization of $5.55 million, a PE ratio of -0.29 and a beta of 2.03. The stock’s 50-day simple moving average is $2.34 and its 200-day simple moving average is $3.07.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Soligenix stock. Geode Capital Management LLC grew its position in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,094 shares of the biopharmaceutical company’s stock after acquiring an additional 7,729 shares during the period. Geode Capital Management LLC owned about 1.04% of Soligenix worth $71,000 at the end of the most recent quarter. Institutional investors and hedge funds own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.